H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Oncolytics Biotech today and set a price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Patrick Trucchio’s rating is based on Oncolytics Biotech achieving a significant regulatory milestone with the FDA, which has endorsed the pivotal Phase 3 trial design for pelareorep in treating first-line metastatic pancreatic ductal adenocarcinoma. This endorsement includes approval of the survival-based primary endpoint and the flexibility to conduct either a two-arm or three-arm study. Such alignment with the FDA reduces regulatory risks and strengthens confidence in pelareorep’s potential across multiple indications, including squamous cell carcinoma of the anal canal and KRAS-mutant metastatic colorectal cancer.
The FDA’s agreement on the trial’s core components, including the study population, endpoints, and treatment schedules, further de-risks the program. The agency’s acceptance of an interim analysis strategy and the potential for accelerated approval also positions pelareorep as a leading candidate in a field lacking approved immuno-oncology options. These factors collectively underpin Trucchio’s Buy rating, reflecting a positive outlook on Oncolytics’ strategic direction and potential market impact.
Trucchio covers the Healthcare sector, focusing on stocks such as Aligos Therapeutics, Precision BioSciences, and Altimmune. According to TipRanks, Trucchio has an average return of 25.6% and a 52.16% success rate on recommended stocks.
In another report released on November 17, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.